News | November 15, 2023
Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
The hospital in association with ‘We Warriors’ and ‘Dev Bhumi Rakshak Foundation’ organized First Aid and CPR training session for youngsters and volunteers
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Subscribe To Our Newsletter & Stay Updated
